Revvity is in a sustained uptrend, with the shares up 45.09% over the past year and 26.65% year-to-date, and the current price of $124.31 sits at roughly 83% of the 52-week range between a low of $81.22 and a high of $133.00. That positioning near the upper end of the range signals persistent momentum rather than deep-value territory, though it also means the stock is within about 7% of its high and therefore more vulnerable to profit-taking. The 45.27% six-month gain confirms the advance has been broad-based rather than a short-lived spike, and the stock has decisively recovered from a maximum drawdown of -30.14%, underscoring how strong the rebound has been from earlier weakness.

Short-term momentum remains positive but is decelerating relative to the longer-term trend: the 1-month change of 5.45% and 3-month change of 24.73% are both solidly positive, yet the 1-month pace is far slower than the 3-month and 6-month rates, suggesting the rally is maturing rather than accelerating. Relative strength tells the same story of leadership, with RVTY beating SPY by 6.51 percentage points over one month, 21.69 points over three months, and 28.87 points over one year, even as the S&P 500 itself fell 1.06% over the past month. The most recent sessions show a pullback from the September 2 high of $130.94 down to $120.94 on September 10 before a 2.79% bounce to $124.31 on September 11, a pattern consistent with a healthy consolidation within an uptrend rather than a trend reversal.

Key technical levels are well defined: support rests near the 52-week low of $81.22, with intermediate support around the $120-$121 area that held during the recent pullback, while resistance sits at the 52-week high of $133.00 and the nearby $130.94 September peak. A breakout above $133 would confirm the uptrend and likely invite momentum buyers, whereas a breakdown below $120 would signal a deeper mean-reversion move toward the $110-$113 zone where the stock consolidated in July. With a beta of 1.089, RVTY is only modestly more volatile than the market, meaning position sizing can be closer to market-neutral, though the 4.14 short ratio and 1.15 million share volume indicate a moderately shorted, reasonably liquid name where squeezes or sharp moves are possible.

Revvity's revenue trajectory has returned to growth, with the most recent quarter (ending April 5, 2026) delivering $711.1 million in revenue, up 6.97% year-over-year, a clear improvement from the prior-year quarterly comparisons. The sequential trend shows $664.8 million in Q1 2025, $720.3 million in Q2 2025, $698.9 million in Q3 2025, $772.1 million in Q4 2025, and $711.1 million in Q1 2026, indicating modest but real top-line expansion with normal seasonality. Segment data shows Life Sciences at $361.8 million and Diagnostics at $349.3 million, a near-even split that gives Revvity balanced exposure to both research spending and clinical demand, with the Life Sciences side likely the key swing factor for growth acceleration given biopharma capex trends.

Profitability is solid and improving on a sequential basis: Q1 2026 net income was $40.7 million on a 54.51% gross margin, with gross profit of $387.7 million, and the trailing net margin stands at 8.46% while the operating margin is 12.49%. Gross margin has been volatile across quarters, ranging from 43.80% in Q4 2025 to 56.49% in Q1 2025, but the latest 54.51% reading is near the high end and above the 53.08% company-level figure, suggesting mix and cost controls are working. Net income of $40.7 million in Q1 2026 was down from $98.4 million in Q4 2025, but that sequential decline reflects normal seasonality and a lower-tax-benefit quarter rather than deterioration, and the 3.33% ROE and 2.37% ROA remain modest but positive, consistent with a capital-intensive instruments business still digesting its post-spinoff structure.

Balance sheet and cash flow metrics are healthy: debt-to-equity is a conservative 0.48, the current ratio is 1.68, and trailing free cash flow is $493.9 million, which comfortably covers the $19.8 million quarterly capex and the $7.8 million dividend. The company generated $115.1 million in operating cash flow in Q1 2026 against $95.3 million of free cash flow, and it returned capital aggressively with $86.5 million of stock repurchased in the quarter, funded from a $860.7 million cash balance. With a dividend yield of just 0.30% and a payout ratio of 13.57%, Revvity retains substantial financial flexibility to fund bolt-on acquisitions, buybacks, or debt reduction, and the low leverage profile means financial risk is not a near-term concern.